Clinical trial · Observational
A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
A Multicenter, Post-Market Follow-up Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
NCT01271959CI-TRIAL-00008223terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research study is to collect information from patient's medical records that had a test called ChemoFx® ordered and to understand how doctors may have used the results of the ChemoFx® to treat patients with cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Organ Tumors | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- To determine physicians' rate of compliance with ChemoFx assay results in the treatment of subjects with solid tumors.
- timeFrame
- Analysis of assay-directed compliance will be conducted immediately after information is collected.
- measure
- To investigate the association between the results of Precision's ChemoFx assay results and overall survival in subjects with solid tumors.
- timeFrame
- From date of first dose of on-study chemotherapy to date of death or last known alive.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed diagnosis of solid tumor malignancy; * Medically indicated to receive chemotherapy; * Fresh tissue submitted from the solid tumor malignancy for testing with the ChemoFx® assay after August, 2006; * Final ChemoFx® assay report is available; * Subject must be at least 18 years of age; * Subject must sign and date an IRB approved ICF. Exclusion Criteria: * Enrolled in PT-103, PT-106, PT-206, PT-301, or PT-304; * Pregnant or lactating subjects; * Subjects are not indicated to receive chemotherapy for their disease; * Subjects with psychiatric or addictive disorders that would preclude obtaining informed consent.
References
Publications (0)
Data not yet available
No reference posted for this study.